Y Intercept Hong Kong Ltd Invests $20.17 Million in Kenvue Inc. $KVUE

Y Intercept Hong Kong Ltd bought a new position in Kenvue Inc. (NYSE:KVUE) in the 2nd quarter, Holdings Channel.com reports. The firm bought 1,055,367 shares of the company’s stock, valued at approximately $20,168,000. Kenvue comprises approximately 0.4% of Y Intercept Hong Kong Ltd’s holdings, making the stock its 29th biggest holding.

Other large investors have also added to or reduced their stakes in the company. Physician Wealth Advisors Inc. boosted its stake in Kenvue by 67.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock worth $26,000 after buying an additional 618 shares in the last quarter. Elyxium Wealth LLC purchased a new position in shares of Kenvue during the fourth quarter worth approximately $26,000. MV Capital Management Inc. purchased a new position in shares of Kenvue during the fourth quarter worth approximately $28,000. CoreCap Advisors LLC lifted its holdings in shares of Kenvue by 64.9% in the 2nd quarter. CoreCap Advisors LLC now owns 1,502 shares of the company’s stock worth $29,000 after acquiring an additional 591 shares during the last quarter. Finally, Reflection Asset Management bought a new stake in Kenvue in the fourth quarter worth $32,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. Zacks Research lowered shares of Kenvue from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 7th. Wall Street Zen downgraded Kenvue from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Citigroup lowered their target price on Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a research note on Wednesday, April 15th. UBS Group dropped their target price on Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a report on Tuesday. Finally, Barclays raised their price target on Kenvue from $18.00 to $19.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 21st. Three research analysts have rated the stock with a Buy rating and twelve have assigned a Hold rating to the stock. According to data from MarketBeat, Kenvue currently has a consensus rating of “Hold” and a consensus target price of $19.27.

Kenvue Stock Performance

Kenvue stock opened at $18.97 on Thursday. The company has a current ratio of 1.01, a quick ratio of 0.71 and a debt-to-equity ratio of 0.67. The firm has a 50-day moving average of $18.88 and a 200-day moving average of $18.12. The firm has a market cap of $36.44 billion, a P/E ratio of 21.80, a P/E/G ratio of 1.36 and a beta of 0.47. Kenvue Inc. has a 1-year low of $14.02 and a 1-year high of $21.95.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.31 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.01). The business had revenue of $3.96 billion for the quarter, compared to analysts’ expectations of $3.97 billion. Kenvue had a net margin of 10.76% and a return on equity of 21.22%. The firm’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.29 EPS. Sell-side analysts expect that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 26th. Stockholders of record on Wednesday, August 12th will be given a $0.21 dividend. The ex-dividend date is Wednesday, August 12th. This represents a $0.84 dividend on an annualized basis and a dividend yield of 4.4%. This is an increase from Kenvue’s previous quarterly dividend of $0.21. Kenvue’s dividend payout ratio is 95.40%.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.